These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 20044279)

  • 1. Treatment with telmisartan attenuates graft arteriosclerosis in murine cardiac allografts.
    Kosuge H; Ishihara T; Haraguchi G; Maejima Y; Okada H; Saiki H; Suzuki J; Isobe M
    J Heart Lung Transplant; 2010 May; 29(5):562-7. PubMed ID: 20044279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pioglitazone prevents acute and chronic cardiac allograft rejection.
    Kosuge H; Haraguchi G; Koga N; Maejima Y; Suzuki J; Isobe M
    Circulation; 2006 Jun; 113(22):2613-22. PubMed ID: 16735678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Telmisartan downregulates angiotensin II type 1 receptor through activation of peroxisome proliferator-activated receptor gamma.
    Imayama I; Ichiki T; Inanaga K; Ohtsubo H; Fukuyama K; Ono H; Hashiguchi Y; Sunagawa K
    Cardiovasc Res; 2006 Oct; 72(1):184-90. PubMed ID: 16938288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Attenuation of graft arterial disease by manipulation of the LIGHT pathway.
    Kosuge H; Suzuki J; Kakuta T; Haraguchi G; Koga N; Futamatsu H; Gotoh R; Inobe M; Isobe M; Uede T
    Arterioscler Thromb Vasc Biol; 2004 Aug; 24(8):1409-15. PubMed ID: 15178556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of tumor necrosis factor-alpha-induced interleukin-6 expression by telmisartan through cross-talk of peroxisome proliferator-activated receptor-gamma with nuclear factor kappaB and CCAAT/enhancer-binding protein-beta.
    Tian Q; Miyazaki R; Ichiki T; Imayama I; Inanaga K; Ohtsubo H; Yano K; Takeda K; Sunagawa K
    Hypertension; 2009 May; 53(5):798-804. PubMed ID: 19289654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interleukin-16 deficiency suppresses the development of chronic rejection in murine cardiac transplantation model.
    Kimura N; Itoh S; Nakae S; Axtell RC; Velotta JB; Bos EJ; Merk DR; Gong Y; Okamura H; Nagamine CM; Adachi H; Kornfeld H; Robbins RC; Fischbein MP
    J Heart Lung Transplant; 2011 Dec; 30(12):1409-17. PubMed ID: 22055099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low dose of telmisartan prevents ischemic brain damage with peroxisome proliferator-activated receptor-gamma activation in diabetic mice.
    Iwanami J; Mogi M; Tsukuda K; Min LJ; Sakata A; Jing F; Iwai M; Horiuchi M
    J Hypertens; 2010 Aug; 28(8):1730-7. PubMed ID: 20498620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Telmisartan inhibits vasoconstriction via PPARγ-dependent expression and activation of endothelial nitric oxide synthase.
    Yuen CY; Wong WT; Tian XY; Wong SL; Lau CW; Yu J; Tomlinson B; Yao X; Huang Y
    Cardiovasc Res; 2011 Apr; 90(1):122-9. PubMed ID: 21156825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The angiotensin II type 1 receptor blocker candesartan attenuates graft vasculopathy.
    Yamamoto T; Sata M; Fukuda D; Takamoto S
    J Surg Res; 2006 May; 132(1):62-8. PubMed ID: 16140337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Telmisartan inhibits vascular dysfunction and inflammation via activation of peroxisome proliferator-activated receptor-γ in subtotal nephrectomized rat.
    Toba H; Tojo C; Wang J; Noda K; Kobara M; Nakata T
    Eur J Pharmacol; 2012 Jun; 685(1-3):91-8. PubMed ID: 22314223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Telmisartan, a dual ARB/partial PPAR-γ agonist, protects myocardium from ischaemic reperfusion injury in experimental diabetes.
    Goyal SN; Bharti S; Bhatia J; Nag TC; Ray R; Arya DS
    Diabetes Obes Metab; 2011 Jun; 13(6):533-41. PubMed ID: 21320264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Telmisartan-induced inhibition of vascular cell proliferation beyond angiotensin receptor blockade and peroxisome proliferator-activated receptor-gamma activation.
    Yamamoto K; Ohishi M; Ho C; Kurtz TW; Rakugi H
    Hypertension; 2009 Dec; 54(6):1353-9. PubMed ID: 19822796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Telmisartan exerts antiatherosclerotic effects by activating peroxisome proliferator-activated receptor-γ in macrophages.
    Matsumura T; Kinoshita H; Ishii N; Fukuda K; Motoshima H; Senokuchi T; Taketa K; Kawasaki S; Nishimaki-Mogami T; Kawada T; Nishikawa T; Araki E
    Arterioscler Thromb Vasc Biol; 2011 Jun; 31(6):1268-75. PubMed ID: 21474824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liver-specific peroxisome proliferator-activated receptor alpha target gene regulation by the angiotensin type 1 receptor blocker telmisartan.
    Clemenz M; Frost N; Schupp M; Caron S; Foryst-Ludwig A; Böhm C; Hartge M; Gust R; Staels B; Unger T; Kintscher U
    Diabetes; 2008 May; 57(5):1405-13. PubMed ID: 18184928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PPARγ attenuates intimal hyperplasia by inhibiting TLR4-mediated inflammation in vascular smooth muscle cells.
    Zhang LL; Gao CY; Fang CQ; Wang YJ; Gao D; Yao GE; Xiang J; Wang JZ; Li JC
    Cardiovasc Res; 2011 Dec; 92(3):484-93. PubMed ID: 21880694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardioprotective mechanism of telmisartan via PPAR-gamma-eNOS pathway in dahl salt-sensitive hypertensive rats.
    Kobayashi N; Ohno T; Yoshida K; Fukushima H; Mamada Y; Nomura M; Hirata H; Machida Y; Shinoda M; Suzuki N; Matsuoka H
    Am J Hypertens; 2008 May; 21(5):576-81. PubMed ID: 18437150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of telmisartan, a unique angiotensin receptor blocker with selective peroxisome proliferator-activated receptor-gamma-modulating activity, on nitric oxide bioavailability and atherosclerotic change.
    Ikejima H; Imanishi T; Tsujioka H; Kuroi A; Kobayashi K; Shiomi M; Muragaki Y; Mochizuki S; Goto M; Yoshida K; Akasaka T
    J Hypertens; 2008 May; 26(5):964-72. PubMed ID: 18398339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Telmisartan modulates mitochondrial function in vascular smooth muscle cells.
    Takeuchi K; Yamamoto K; Ohishi M; Takeshita H; Hongyo K; Kawai T; Takeda M; Kamide K; Kurtz TW; Rakugi H
    Hypertens Res; 2013 May; 36(5):433-9. PubMed ID: 23254392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distinct properties of telmisartan on agonistic activities for peroxisome proliferator-activated receptor γ among clinically used angiotensin II receptor blockers: drug-target interaction analyses.
    Kakuta H; Kurosaki E; Niimi T; Gato K; Kawasaki Y; Suwa A; Honbou K; Yamaguchi T; Okumura H; Sanagi M; Tomura Y; Orita M; Yonemoto T; Masuzaki H
    J Pharmacol Exp Ther; 2014 Apr; 349(1):10-20. PubMed ID: 24424487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Telmisartan protects against vascular dysfunction with peroxisome proliferator-activated receptor-γ activation in hypertensive 5/6 nephrectomized rats.
    Toba H; Wang J; Ohigashi M; Kobara M; Nakata T
    Pharmacology; 2013; 92(5-6):265-75. PubMed ID: 24281041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.